Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DWIGHT DENMAN BLAKE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1811938814
CMS profile
173473
Location
UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,138.93

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $615.32 3
Food and Beverage $523.61 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $896.67 4
Metuchen Pharmaceuticals $125.00 1
Boehringer Ingelheim Pharmaceuticals, Inc. $117.26 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DWIGHT DENMAN BLAKE

NPI 1811938814 · CMS profile ID 173473

Allopathic & Osteopathic Physicians / Internal Medicine

UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $1,138.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $117.2609/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700035649 CMS
Metuchen Pharmaceuticals $125.0008/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679321141 CMS
Eli Lilly and Company $281.3502/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657785989 CMS
Eli Lilly and Company $182.8502/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657785991 CMS
Eli Lilly and Company $85.0102/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657803229 CMS
Eli Lilly and Company $347.4602/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657785987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,138.93 6
PY2020 $1,159.49 24
PY2021 $122.45 1
PY2022 $473.01 5
PY2024 $1,818.96 5
PY2025 $369.25 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,386,564.75 80
PY2024 Recipient $57,732.20 4
PY2024 Principal investigator $2,455,115.26 49
PY2023 Recipient $2,277.99 4
PY2023 Principal investigator $2,791,306.83 51
PY2022 Recipient $92,276.00 3
PY2022 Principal investigator $3,022,384.19 43
PY2021 Recipient $6,646.99 2
PY2021 Principal investigator $1,337,039.14 22
PY2020 Recipient $1,658.45 3
PY2020 Principal investigator $145,341.90 6
PY2019 Recipient $24,425.96 3
PY2019 Principal investigator $177,128.41 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
SP RESEARCH PLLC
M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) No dispute reported 06/30/2026 1100766421
Principal investigator 1 Merck Sharp & Dohme LLC $22,862.79 12/31/2024 Non-covered Recipient Entity
Rophe Adult and Pediatric Medicine,SKYCRNG
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419605
Principal investigator 1 Merck Sharp & Dohme LLC $5,185.28 12/31/2024 Non-covered Recipient Entity
Rophe Adult and Pediatric Medicine,SKYCRNG
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419610
Principal investigator 1 PFIZER INC. $19,785.00 12/17/2024 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1130945658
Principal investigator 1 Chiesi USA, Inc. $2,500.00 12/06/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225590
Principal investigator 1 Merck Sharp & Dohme LLC $19,050.00 12/04/2024 Non-covered Recipient Entity
Rophe Adult and Pediatric Medicine,SKYCRNG
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419601
Principal investigator 1 PFIZER INC. $2,257.20 11/20/2024 Non-covered Recipient Entity
Rophe Adult and Pediatric MedicineSKYCRNG
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1130916321
Principal investigator 1 PFIZER INC. $853.20 11/20/2024 Non-covered Recipient Entity
Rophe Adult and Pediatric MedicineSKYCRNG
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1130917783
Principal investigator 1 PFIZER INC. $156.00 11/20/2024 Non-covered Recipient Entity
ROPHE ADULT PED MEDSKYCRNG
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1130945652
Principal investigator 1 PFIZER INC. $139.95 11/20/2024 Non-covered Recipient Entity
ROPHE ADULT PED MEDSKYCRNG
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1130945753
Principal investigator 1 Eli Lilly and Company $285.16 11/18/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1137367057
Principal investigator 1 Chiesi USA, Inc. $1,125.00 11/13/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224888
Principal investigator 1 Eli Lilly and Company $267,186.00 10/29/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1137366875
Principal investigator 1 Chiesi USA, Inc. $1,125.00 10/23/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224280
Recipient Eli Lilly and Company $2,869.00 10/15/2024 Covered Recipient Physician A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137347244
Recipient Eli Lilly and Company $49,905.00 09/24/2024 Covered Recipient Physician A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137346906
Recipient Eli Lilly and Company $4,859.00 09/24/2024 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137347242
Principal investigator 1 Chiesi USA, Inc. $3,625.00 09/18/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223202
Principal investigator 1 Galderma Laboratories, L.P. $29,025.00 09/05/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156049303
Recipient Eli Lilly and Company $99.20 08/26/2024 Covered Recipient Physician A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1137345750
Principal investigator 1 Chiesi USA, Inc. $7,209.00 08/14/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148222408
Principal investigator 1 Eli Lilly and Company $505.00 08/08/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137367717
Principal investigator 1 ABBVIE INC. $2,801.14 08/02/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100735002
Principal investigator 1 Chiesi USA, Inc. $11,920.00 07/24/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221560
Principal investigator 1 Galderma Laboratories, L.P. $25,285.00 07/11/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156048987
Principal investigator 1 ABBVIE INC. $3,398.96 07/05/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100728172
Principal investigator 1 Chiesi USA, Inc. $2,500.00 06/28/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221062
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $9,905.91 06/27/2024 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1095482546
Principal investigator 1 ABBVIE INC. $2,288.52 06/06/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100722556
Principal investigator 1 Galderma Laboratories, L.P. $379.13 05/30/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1156048761
Principal investigator 1 Chiesi USA, Inc. $5,960.00 05/15/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148219906
Principal investigator 1 ABBVIE INC. $5,812.44 05/08/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100716498
Principal investigator 1 PFIZER INC. $15,300.00 04/05/2024 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1131087866
Principal investigator 1 PFIZER INC. $5,787.50 03/29/2024 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131100420
Principal investigator 1 ABBVIE INC. $1,098.82 03/07/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100707614
Principal investigator 1 Chiesi USA, Inc. $10,000.00 02/21/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148216196
Principal investigator 1 PFIZER INC. $295.40 02/21/2024 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130992616
Principal investigator 1 Eli Lilly and Company $10,248.00 02/13/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137367855
Principal investigator 1 Eli Lilly and Company $101,139.00 02/06/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137367511
Principal investigator 1 ABBVIE INC. $2,933.20 02/01/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100702192
Principal investigator 1 Eli Lilly and Company $147.60 01/31/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137367735
Principal investigator 1 Eli Lilly and Company $16,474.00 01/30/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137366365
Principal investigator 1 Eli Lilly and Company $1,280.04 01/12/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1137366853
Principal investigator 1 Eli Lilly and Company $1,129.84 01/12/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137367413
Principal investigator 1 Eli Lilly and Company $3,607.65 01/12/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137367415
Principal investigator 1 Eli Lilly and Company $1,557.09 01/12/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1137367729
Principal investigator 1 Eli Lilly and Company $1,309.56 01/10/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1137366871
Principal investigator 1 Eli Lilly and Company $118,530.00 01/08/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137367723
Principal investigator 1 ABBVIE INC. $4,003.88 01/04/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100698871
Principal investigator 1 Eli Lilly and Company $742,634.00 01/02/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1137366845
Principal investigator 1 Eli Lilly and Company $96,659.00 01/02/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1137366847
Principal investigator 1 Eli Lilly and Company $451,836.00 01/02/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1137367061
Principal investigator 1 Eli Lilly and Company $415,092.00 01/02/2024 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137367063